Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation

Statistics in Medicine

Volumn 28, Issue 14, 2009, Pages 1861-1881

  Cooper, Nicola J ^a   Sutton, Alex J ^a,d   Morris, Danielle ^b   Ades, A E ^c,d   Welton, Nicky J ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d Department of Medical Statistics ^*

Author keywords

Atrial fibrillation; Heterogeneity; Mixed treatment comparison

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; INDOBUFEN; PLACEBO; TRIFLUSAL; WARFARIN; XIMELAGATRAN;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COVARIANCE; DECISION MAKING; FEASIBILITY STUDY; HEART ATRIUM FIBRILLATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; META ANALYSIS; MIXED TREATMENT COMPARISON; MONTE CARLO METHOD; MORBIDITY; MORTALITY; PROBABILITY; STATISTICAL MODEL; THERAPY EFFECT;

ALGORITHMS; ANALYSIS OF VARIANCE; ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; LOGISTIC MODELS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TREATMENT OUTCOME;

EID: 69949092149     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3594     Document Type: Article

References (38)

1. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-analysis in Medical Research. Wiley: Chichester, England, 2000.
2. Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. British Medical Journal 2005; 331:897-900.
3. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004; 23:3105-3124.
4. Higgins JPT, Whitehead A. Borrowing strength from external trials in a meta-analysis. Statistics in Medicine 1996; 15:2733-2749.
5. Lumley T. Network meta-analysis for indirect treatment comparisons. Statistics in Medicine 2002; 21:2313-2324.
6. Dersimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7:177-188.
7. Dersimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary Clinical Trials 2007; 28:105-114.
8. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Statistics in Medicine 1999; 18:2693-2708.
9. Lu G, Ades AE. Assessing evidence consistency in mixed treatment comparisons. Journal of the American Statistical Association 2006; 101:447-459.
10. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS User Manual: Version 1.4. MRC Biostatistics Unit: Cambridge, 2003.
11. Dempster AP. The direct use of likelihood for significance testing. Statistics and Computing 1997; 7:247-252.
12. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society, Series B 2002; 64(4):583-639.
13. Welton NJ, Ades AE. A model of toxoplasmosis incidence in the U.K.: evidence synthesis and consistency of evidence. Journal of the Royal Statistical Society, Series C 2005; 54(2):385-404.
14. Goyal D, Choudhary A, Lip GYH. Managing atrial fibrillation. Practical Cardiovascular Risk Management 2005; 3(2):2-5.
15. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the Anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Journal of the American Medical Association 2001; 285(18):2370-2375.
16. Iqbal MB, Taneja AK, Lip GYH, Flather M. Recent developments in atrial fibrillation. British Medical Journal 2005; 330:238-243.
17. Stewart S, Hart CL, Hole DJ, McMurray JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of Renfrew/Paisley study. American Journal of Medicine 2002; 113:359-364.
18. Segal JB, McNamara RL, Miller MR, Powe NR. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter (Review). The Cochrane Database of Systematic Reviews 2001; CD001938 (1).
19. Green CJ, Hadorn DC, Bassett K, Kazanjian A. Anti-coagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis. Canadian Journal of Cardiology 1997; 13(9):811-815.
20. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Annals of Internal medicine 1999; 131:492-501.
21. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson KA, Bass EB. Prevention of thromboembolism in atrial fibrillation: a meta-analysis of trials of anti-coagulants and antiplatelet drugs. Journal of General Internal Medicine 2000; 15:56-67.
22. Taylor FC, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. British Medical Journal 2001; 322:321-326.
23. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. Journal of the American Medical Association 2002; 288:2441-2448.
24. Singer DE. Overview of the randomized controlled trials to prevent stroke in atrial fibrillation. Annals of Epidemiology 1993; 3(5):563-567.
25. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine 2007; 146:857-867.
26. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Archives of Internal Medicine 2006; 166:1269-1275.
27. Mant J, Hobbs R, Fltcher K, Roalfe A, Fitzmaurice D, Lip GYH, Murray E. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. The Lancet 2007; 370:493-593.
28. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Aging 2007; 36:151-156.
29. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004; 23:1351-1375.
30. Gilks WR, Richardson S, Spiegelhalter DJ. Markov Chain Monte Carlo in Practice: Interdisciplinary Statistics. Chapman & Hall: London, 1996.
31. Nixon R, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Statistics in Medicine 2007; 26:1237-1254.
32. Lambert PL, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient level covariates in meta-regression with individual patient data meta-analyses. Journal of Clinical Epidemiology 2002; 55:86-94.
33. Goubar A, Ades AE, De Angelis D, McGarrigle CA, Mercer C, Tookey P, Fenton K, Gill ON. Estimates of HIV prevalence and proportion diagnosed based on Bayesian multi-parameter synthesis of surveillance data. Journal of the Royal Statistical Society 2008; 171(Part 3):541-580.
34. Sutton AJ, Kendrick D, Coupland CAC. Meta-analysis of individual- and aggregate-level data. Statistics in Medicine 2008; 27:651-669.
35. Thompson SG, Smith TC, Sharp SJ. Investigating underlying risk as a source of heterogeneity in meta-analysis. Statistics in Medicine 1997; 16:2741-2758.
36. Welton NJ, Cooper NJ, Ades AE, Lu G, Sutton AJ. Mixed treatment comparison with multiple outcomes reported inconsistently across trials: evaluation of antivirals for treatment of influenza A and B. Statistics in Medicine 2008; 27(27):5620-5639.
37. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC. Statistics in Medicine 2005; 24(15):2401-2428.
38. Ades AE, Lu G, Higgins JPT. The interpretation of random-effects meta-analysis in decision models. Medical Decision Making 2005; 25:646-654.